Delivery Order SPE2DB20D3103-SPE2DB24FN8F5

Award Date 5/14/24
Potential Completion Date 5/15/24
Potential Value $7.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,887.13 firm fixed-price delivery order is for the supply of 4566747173 ! XYLOCAINE 1%-EPI 1:100,000 50ML, a pharmaceutical product. The contract has an ultimate completion date of December 18, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, valued at $2,686.11, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which is a $999,999,999 IDC that runs through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of...
This federal contract award, with ID SPE2DX15D1104|SPE2DX24F3FH9, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp. The $1,037.22 firm fixed-price delivery order is for the pharmaceutical product XYLOCAINE-MPF 2% VIAL 5ML, with an ultimate completion date of October 27, 2023. This award is part of Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of XYLOCAINE-MPF 1% VIAL 5ML, a local anesthetic medication. The contract is a Delivery Order with a Firm Fixed Price of $1,386.88 and an ultimate completion date of September 5, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999...
This federal contract award, valued at $3,731.66, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of XYLOCAINE-MPF 2% AMPUL 10ML, a medical product. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC...
This federal contract award is for the delivery of Xylocaine-MPF 2% 40 mg/2 ml vials to the Defense Logistics Agency (DLA). The contract, valued at $6,221.86, was awarded to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. This is a delivery order contract with a firm fixed price pricing type, and the ultimate completion date is March 18, 2024. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of Xylocaine-MPF 1% vial 5ML pharmaceutical products to the Defense Logistics Agency (DLA). The contract has a ceiling value of $1,173.76 and is a Firm Fixed Price Delivery Order with a completion date of May 24, 2024. This award is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through December 31,...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,370.88 Firm Fixed Price Delivery Order is for the supply of Xylocaine-MPF 2% Ampul 10ML, a local anesthetic medication. The award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves as the primary...
This federal contract award is for the delivery of Lidocaine HCL 2% 200 mg/10 mL 10 mL to the Defense Logistics Agency (DLA). The $2,086.24 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract has an ultimate completion date of December 6, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to...
This federal contract award, valued at $2,243.35, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XYLOCAINE 2%-EPI 1:100,000 20ML, a pharmaceutical product, and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB24FN8F5
    Delivery Order

This federal contract award, valued at $7,148.42, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under the company's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The specific award is for XYLOCAINE-MPF 2% 40 MG/2 ML VL 2ML, a generic injectable medication, with a performance period extending through May 15, 2024. The contract was awarded on a Firm Fixed Price basis and did not have any set-aside designation, indicating open competition.

Generated 5/16/25, 12:02 PM